The Quebec Consortium
for Drug Discovery has announced C$1.2 million in funding for
a quartet of projects that are smaller and riskier than those the consortium
has been funding since its inception. For all the projects the consortium
funds, it expects the results will yield useful research tools for the
consortium's pharma members.
M.J. SciBX 4(41);
doi:10.1038/scibx.2011.1135 Published online Oct. 20, 2011
Alsace BioValley, Illkirch, France
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Biotechnology Research Institute, Montreal, Quebec, Canada
Boehringer Ingelheim GmbH, Ingelheim, Germany
Caprion Proteomics Inc., Montreal, Quebec, Canada
Domain Therapeutics S.A., Illkirch, France
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
de recherche du Québec-Santé, Montreal, Quebec, Canada
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Cellular and Integrative Neurosciences, Strasbourg, France
of Genetics and Molecular and Cell Biology, Illkirch, France
, Quebec City, Quebec, Canada
McGill University, Montreal, Quebec, Canada
Medicago Inc. (TSX:MDG), Quebec City, Quebec, Canada
Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J.
Biotech Services Inc.,
Montreal, Quebec, Canada
Research Council Canada,
Ottawa, Ontario, Canada
NDEI Inc., Sainte-Foy, Quebec, Canada
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Photon etc., Montreal, Quebec, Canada
Polytechnique Montreal, Montreal, Quebec, Canada
Consortium for Drug Discovery, Montreal, Quebec, Canada
Rhenovia Pharma S.A.S., Mulhouse, France
of Montreal, Montreal,